Humacyte (NASDAQ:HUMA) Announces Quarterly Earnings Results, Hits Estimates

Humacyte (NASDAQ:HUMA) announced its earnings results on Friday. The company reported ($0.13) EPS for the quarter, meeting analysts’ consensus estimates of ($0.13), FiscalAI reports. The firm had revenue of $0.47 million for the quarter, compared to analysts’ expectations of $1.35 million.

Here are the key takeaways from Humacyte’s conference call:

• Commercial launch momentum for Symvess — 27 VAC approvals to date, 43 VAC reviews pending, 27 hospitals have ordered (most reordering), and the price cut to $17,000 has raised VAC success to ~70% and increased repeat usage.
• First-of-its-kind U.S. Department of Defense funding has been allocated for procurement and training of biologic vascular repair technologies, which could drive meaningful adoption and non‑commercial volume in 2026.
• Dialysis access is a near-term regulatory catalyst: positive V007 two‑year results support ATEV, the V012 interim analysis (first 80 patients to one year) will report by early June 2026, and Humacyte plans a supplemental BLA submission in H2 2026 if results are supportive.
• Financial mix is mixed — Q4 net loss widened to $24.8M largely due to an $8.9M inventory reserve and unused capacity costs, but FY25 net loss improved to $40.8M year-over-year and liquidity was bolstered by ~$50M cash at year‑end plus subsequent equity raises and a $40M initial tranche of a $77.5M credit facility.
• Pipeline progress beyond trauma — the CTEV coronary graft completed positive preclinical work, an IND was submitted and commercial-scale manufacturing started, targeting first‑in‑human coronary trials in H2 2026.

Humacyte Stock Down 9.2%

NASDAQ:HUMA traded down $0.07 during mid-day trading on Friday, hitting $0.71. The stock had a trading volume of 7,998,058 shares, compared to its average volume of 6,664,996. Humacyte has a twelve month low of $0.70 and a twelve month high of $2.93. The stock has a 50-day simple moving average of $1.05 and a two-hundred day simple moving average of $1.29. The company has a current ratio of 1.62, a quick ratio of 0.90 and a debt-to-equity ratio of 2.97. The company has a market capitalization of $132.40 million, a PE ratio of -3.07 and a beta of 1.89.

Wall Street Analysts Forecast Growth

Several brokerages have recently issued reports on HUMA. HC Wainwright reissued a “buy” rating and set a $3.00 price target on shares of Humacyte in a research report on Monday, December 1st. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Humacyte in a research note on Monday, December 29th. Benchmark decreased their price target on shares of Humacyte from $11.00 to $10.00 and set a “buy” rating for the company in a research report on Wednesday, January 21st. Wall Street Zen downgraded shares of Humacyte from a “hold” rating to a “sell” rating in a research note on Sunday, December 21st. Finally, UBS Group reaffirmed a “buy” rating on shares of Humacyte in a research report on Monday, December 1st. Seven investment analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average target price of $7.71.

Institutional Investors Weigh In On Humacyte

A number of hedge funds and other institutional investors have recently modified their holdings of the company. Virtu Financial LLC purchased a new stake in shares of Humacyte during the 4th quarter worth $252,000. XTX Topco Ltd lifted its holdings in Humacyte by 236.1% during the 4th quarter. XTX Topco Ltd now owns 650,858 shares of the company’s stock worth $625,000 after buying an additional 457,236 shares during the last quarter. Quadrature Capital Ltd acquired a new position in shares of Humacyte during the 4th quarter worth about $201,000. Millennium Management LLC increased its holdings in shares of Humacyte by 129.5% in the 4th quarter. Millennium Management LLC now owns 2,631,990 shares of the company’s stock valued at $2,528,000 after acquiring an additional 1,485,152 shares during the last quarter. Finally, Engineers Gate Manager LP acquired a new stake in shares of Humacyte during the 4th quarter worth about $82,000. 44.71% of the stock is currently owned by institutional investors and hedge funds.

Key Headlines Impacting Humacyte

Here are the key news stories impacting Humacyte this week:

• Positive Sentiment: Humacyte appointed Rick McElheny as SVP of Business Development to expand corporate collaborations and commercialization efforts, which could help accelerate partnerships and non‑dilutive revenue opportunities. Humacyte Appoints Rick McElheny
• Neutral Sentiment: Management held its Q4/FY2025 earnings call and published a press release and transcript — listen/read for management commentary on revenue drivers, cash runway, and timing of commercial or partnership milestones. Press Release and Call
• Negative Sentiment: Q4 results: EPS of ($0.13) met consensus but revenue of ~$0.47–0.5M missed estimates (~$1.35M), signaling slower near‑term commercial or collaboration receipts; weaker top‑line drove investor disappointment. Earnings Release
• Negative Sentiment: BTIG trimmed its price target from $6.00 to $3.00 (retaining a Buy rating). The large cut reduces implied upside and likely pressured sentiment despite the Buy stance. BTIG Coverage Note
• Negative Sentiment: Analyst writeups (Zacks and others) flagged the revenue miss and reiterated the loss per share profile; watch for any guidance or cash‑runway detail in filings/call that could further affect risk perception. Zacks Coverage

Humacyte Company Profile

Humacyte, Inc is a clinical-stage biotechnology company focused on the development and manufacturing of off-the-shelf, regenerative human acellular vessels (HAVs) designed to address critical vascular access needs. The company’s proprietary vessels are engineered from human donor cells and then decellularized to create a biocompatible scaffold capable of integrating with a patient’s own tissue. Humacyte’s primary business activities encompass process development, large-scale manufacturing, and clinical evaluation of HAVs for use in end-stage renal disease, peripheral arterial disease and other vascular repair applications.

The company’s lead product candidate, the HAV, has advanced through multiple clinical trials for arteriovenous access in hemodialysis patients, demonstrating durability, reduced infection rates and compatibility with repeated cannulation.